GPP
VIRX

Great Point Partners’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Great Point Partners’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,905
Closed -$2.86M – 38
2014
Q3 		$2.86M Buy
+1,905
New +$2.76M 1.23% 26

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Great Point Partners's VIRX Position: Q1 2019 in Review

Great Point Partners sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2019, closing a stake of 9,085 shares — an estimated $132K sold.

Great Point Partners first reported a position in VIRX in Q1 2014 and held it in 14 quarters. The position peaked at $7.65M in Q2 2015. 44 funds tracked by Wall St. Rank hold VIRX as of Q1 2019.

  • Great Point Partners reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Great Point Partners sold 9,085 Viracta Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $132K.
  • Great Point Partners first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2014 and held it in 14 quarters.
  • Great Point Partners's Viracta Therapeutics, Inc. Common Stock position peaked at $7.65M in Q2 2015.
  • 44 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Great Point Partners's 13F filing for Q1 2019, filed 14 May 2019.